The following guideline can be ordered through the address listed in the "Source/Publisher"-category. In cases in which you can order through the Internet we have established a hyperlink.

FDA Guidance for Industry: CMC Postapproval Manufacturing Changes for Specific Biological Products To Be Documented in Annual Reports



This guidance provides recommendations to holders of biologics license applications (BLAs) for specified products regarding the types of changes to an approved BLA to be documented in an annual report under 21 CFR 601.12.

Go back

GMP Conferences by Topics